氢化可的松(Hydrocortisone) - 药物靶点：GR_在研适应症：先天性肾上腺增生，孤立性ACTH缺乏症，肾上腺皮质功能不全_专利_临床

概要

基本信息

简介氢化可的松是一种小而强大的分子，以其作为糖皮质激素受体 (GR) 激动剂的能力而闻名，从而刺激 GR。该药物具有广泛的临床应用，通常用于治疗与肾上腺功能不全密切相关的多种疾病，包括但不限于先天性肾上腺增生、肾上腺增生、艾迪生病和孤立性促肾上腺皮质激素缺乏症。此外，它已被证明可有效治疗亚急性甲状腺炎、溃疡性结肠炎、直肠结肠炎和溃疡性直肠炎等炎症。值得注意的是，FDA 最初于 1952 年 8 月 5 日批准了氢化可的松。氢化可的松的开发归功于该药物的先驱 Merck Sharp & Dohme Corp。由于其非凡的抗炎和免疫抑制特性，氢化可的松已成为许多慢性炎症性疾病的最终药物。

药物类型

小分子化药

别名

(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione、11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione、11beta-hydrocortisone

+ [58]

靶点

GR

作用机制

GR激动剂(糖皮质激素受体激动剂)

治疗领域

肿瘤免疫系统疾病感染+ [10]

在研适应症

先天性肾上腺增生孤立性ACTH缺乏症肾上腺皮质功能不全+ [19]

非在研适应症

淋巴母细胞淋巴瘤21-羟化酶缺乏症引起的先天性肾上腺皮质增生非霍奇金淋巴瘤+ [3]

原研机构

Merck Sharp & Dohme Corp.

在研机构

ANI Pharmaceuticals, Inc.

Neurocrine Biosciences, Inc.Pharmacia & Upjohn, Inc.

+ [4]

非在研机构

Merck & Co., Inc.

Takeda Pharmaceutical Co., Ltd.

Shire Plc

最高研发阶段批准上市

首次获批日期

美国 (1952-08-05),

内分泌系统疾病超敏反应免疫系统疾病+ [1]

最高研发阶段(中国)批准上市

特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (澳大利亚)

登录后查看时间轴

结构/序列

分子式C21H30O5

InChIKeyJYGXADMDTFJGBT-VWUMJDOOSA-N

CAS号50-23-7

关联

465

项与氢化可的松相关的临床试验

NCT06381661

/ Not yet recruiting临床3期IIT

PALETTE- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Bayesian Basket Trial"

PALETTE is a perpetual adaptive platform to efficiently study sepsis interventions within 'treatable traits' in all-ages patients enabling prompt evaluation of pandemic treatments. Treatable traits, therapeutic targets identified by phenotypes or endotypes (defined by biological mechanism or by treatment response) through validated biomarkers (measurable characteristic reflecting normal or pathogenic processes, or treatment responses), may include multi-omics, cellular, immune, metabolic, endocrine features, or intelligent algorithms. PALETTE Bayesian adaptive design enables parallel investigations of multiple interventions for sepsis, and quick inclusion of pandemic pathogens. PALETTE's new conceptual model will respond to the challenges of standard approaches, i.e. series of sepsis trials, each investigating one or two interventions, expensive, time consuming, and inappropriate in pandemic context.

开始日期2026-04-01

申办/合作机构

Assistance Publique des Hôpitaux de Paris SA

NCT04231708

/ Not yet recruiting临床2期IIT

Effects of Pharmacological Stress and Repetitive Transcranial Magnetic Stimulation Interventions on Executive Function in Opioid Use Disorder

This preliminary study is designed to evaluate mechanisms by which excitatory dorsolateral prefrontal cortex (dlPFC) repetitive transcranial magnetic stimulation (rTMS) (vs. sham) and pharmacological stress (vs. placebo) alter behavior in non-treatment seeking individuals with opioid use disorder (OUD). Specific Aims are to (1) Evaluate how stress impacts domains of behavior including (1a) executive function and (1b) opioid-seeking behavior; and (2) Determine whether rTMS stimulation attenuates (2a) executive dysfunction, (2b) stress-reactivity, and (2c) opioid-seeking in individuals with OUD not receiving treatment.

开始日期2025-06-01

申办/合作机构

Wayne State University (Michigan)

NCT06317662

/ Not yet recruiting临床2期IIT

A Phase 2 Study of Blinatumomab in Combination With Chemotherapy for Infants With Newly Diagnosed Acute Lymphoblastic Leukemia With Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax

This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged [R]) or without a KMT2A gene rearrangement (KMT2A-germline [G]). Venetoclax is in a class of medications called B-cell lymphoma-2 (Bcl-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Blinatumomab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding venetoclax and/or blinatumomab to standard chemotherapy may be more effective at treating patients with ALL than standard chemotherapy alone, but it may also cause more side effects. This clinical trial evaluates the safety and effectiveness of adding venetoclax and/or blinatumomab to chemotherapy for the treatment of infants with KMT2A-R or KMT2A-G ALL.

开始日期2025-04-26

申办/合作机构

National Cancer Institute

100 项与氢化可的松相关的临床结果

登录后查看更多信息

100 项与氢化可的松相关的转化医学

登录后查看更多信息

100 项与氢化可的松相关的专利（医药）

登录后查看更多信息

91,096

项与氢化可的松相关的文献（医药）

2025-12-31·STRESS-THE INTERNATIONAL JOURNAL ON THE BIOLOGY OF STRESS

Differences in hair cortisol to cortisone ratio between depressed and non-depressed adolescent women

Article

作者: Garel, Patricia ; Porter-Vignola, Elyse ; Herba, Catherine M. ; Marin, Marie-France ; Zerroug, Yasmine

Research on stress has demonstrated that the hypothalamic-pituitary-adrenal (HPA) axis contributes to major depressive disorder in youth. Hair glucocorticoids are key biological markers of chronic stress. We assessed group differences in hair cortisol and cortisone concentrations, and the cortisol/cortisone ratio between depressed adolescent women and a non-depressed comparison group. Further, within the depression group, we explored the contribution of symptom severity and clinical correlates of depression in relation to glucocorticoid concentrations. Hair samples of three centimeters for 74 adolescent women (41 in the depression group and 33 in the comparison group), aged between 12 and 19 years old, were analyzed. Depressive and anxiety symptoms were measured using the Beck Youth Inventory II and clinical correlates of depression were measured using the Childhood Trauma Questionnaire-Short Form and the Borderline Personality Features Scale for Children. No significant differences emerged between the depression group and the comparison group on hair cortisol or hair cortisone concentrations. However, groups differed significantly on the cortisol/cortisone ratio, a proposed proxy of 11-beta-hydroxysteroid dehydrogenase activity, with a higher ratio for the depression group. Within the depression group, neither symptom severity nor clinical correlates were associated with glucocorticoid concentrations. Although cross-sectional, our findings highlight the importance of future studies to test whether the group difference found in cortisol/cortisone ratio is the result of alterations in 11-beta-hydroxysteroid dehydrogenase enzymes (type 1 or 2) activity. Further research is thus needed to clarify the role of these enzymes in major depressive disorder in youth and to develop more targeted intervention strategies.

2025-12-31·ANNALS OF MEDICINE

High-dose glucocorticoid treatment vs. glucocorticoid replacement in immune checkpoint inhibitor associated hypophysitis (CORTICI): an open, randomised controlled trial

Article

作者: Obermayer-Pietsch, Barbara ; Theiler-Schwetz, Verena ; Pilz, Stefan ; Schmitt, Lisa ; Trummer, Christian ; Richtig, Erika ; Terbuch, Angelika

OBJECTIVE:

One of the most severe endocrine side effects of immune checkpoint inhibitors (ICI) is hypophysitis leading to adrenal insufficiency. Recovery is rare, although it has been reported after high-dose glucocorticoid treatment. This is the first randomised study to evaluate whether hormonal recovery differs in patients treated with high-dose glucocorticoids versus glucocorticoid replacement therapy.

DESIGN/METHODS:

In this single-centre, open, randomised controlled study, patients with ICI associated hypophysitis were randomised 1:1 to high-dose glucocorticoid treatment (1 mg/kg of prednisolone for two weeks, followed by tapering until week 7 and a switch to hydrocortisone 20 mg total daily dose in week 8) or glucocorticoid replacement therapy (hydrocortisone 20 mg total daily dose) over 8 weeks. The primary outcome was the frequency of hormonal axes recovery.

RESULTS:

Between 17th April 2019 and 16th September 2022, 18 out of the 20 randomised patients finished the trial; eight completed high-dose, 10 glucocorticoid replacement. Nine patients presented with hyponatraemia, two had typical changes on MRI, 12 had isolated adrenal insufficiency, and six had an additional hormone deficiency. None of the patients in neither group experienced a recovery in adrenal function. One patient in each group showed amelioration of hypogonadism. There was a significant, unfavourable treatment effect of high-dose treatment on HbA1c (mean treatment effect 5.16, 95% confidence interval 0.31 to 10.02, p = 0.039).

CONCLUSIONS:

High-dose glucocorticoid treatment was not effective in restoring adrenal function and leads to adverse effects on glucose metabolism. We therefore do not recommend its use for the treatment of ICI associated hypophysitis, except for compressive symptoms.

2025-06-01·BIOELECTROCHEMISTRY

Conductive and flexible gold-coated polylactic acid nanofiber-based electrochemical aptasensor for monitoring cortisol level in sweat and saliva

Article

作者: Koumbia, Mkliwa ; Madoka, Takai

Conductive nanofibers can exhibit excellent mechanical properties such as flexibility, elasticity, porosity, large surface area-to-volume ratio, etc making them suitable for a wide range of applications including biosensor development. Their large surface area provides more active sites for immobilization of large amount of bioreceptors enabling more interaction sites with the target analytes, enhancing sensitivity and detection capabilities. However, engineering conductive nanofibers with such excellent properties is challenging limiting their effective deployment for intended applications. In this research, we propose a novel approach for easy fabrication of highly conductive and flexible nanofiber leveraging the electrospinning, electroless deposition and have applied it to cortisol monitoring; a common biomarker for stress which is often quantified through enzyme-linked immunoassays using blood or saliva samples. By adopting the nanofiber sheet as a transducer for aptamer immobilization and cortisol sensing our developed biosensor was able to detect cortisol in buffer, artificial saliva, and artificial sweat within five minutes, from 10 pg/mL to 10 µg/mL (27.59 pM to 27.59 µM) with a low detection limit of 1 pg/ml (2.76 pM). The Au-coated PLA nanofiber-based electrochemical biosensor's flexibility allows for compact manufacturing, rendering it an optimal choice for integration into point-of-care testing and wearable systems.

153

项与氢化可的松相关的新闻（医药）

2025-02-07

·ir.etonpharma.com

Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600

« Back to news - Product has patent protection through 2044 - - Expected to be listed in the U.S. Food and Drug Administration’s (FDA) Orange Book upon the product’s approval – DEER PARK, Ill., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company U.S. Patent No. 12,214,010, covering its ET-600 product candidate’s proprietary formulation of desmopressin oral solution. The patent expires in 2044 and is expected to be listed in the FDA Orange Book upon the product’s approval. The Company has an additional patent application related to the product under review with the USPTO. ET-600 is a proprietary formulation of desmopressin oral solution under development for the treatment of diabetes insipidus. Desmopressin is the standard of care for diabetes insipidus, but there is not an FDA-approved oral liquid formulation. Currently, desmopressin is only FDA-approved in injectable, tablet, and nasal form, none of which fully meet the pediatric need for small, precise, and titratable doses. As a result, most pediatric patients use unapproved liquid suspensions from compounding pharmacies, attempt to cut and measure fractional tablets, or take daily injections. “This patent strengthens our growing intellectual property portfolio and underscores our commitment to delivering innovative treatments to underserved patient populations. The pediatric endocrinology community has expressed the significant need for a liquid form of desmopressin that can accurately and efficiently deliver small doses for children, and we are proud to have developed a formulation to meet their needs and to see our innovation recognized with a patent,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. ET-600 previously passed a pilot bioequivalence study in 2024 and is currently undergoing its pivotal bioequivalence study. The Company expects to have study results at the end of February. If results are positive, the company anticipates filing a New Drug Application (NDA) with the FDA for the product by the second quarter of 2025. About Diabetes Insipidus Diabetes insipidus is a rare condition in which the body produces too much urine and is not able to retain water. If left untreated, diabetes insipidus can cause excessive dehydration and delayed or stunted growth in children. The condition is estimated to affect about 1 in 25,000 people, or approximately 3,000 pediatric patients in the United States. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: ET-400, ET-600, Amglidia®, and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Relations: Lisa M. Wilson, In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com Source: Eton Pharmaceuticals, Inc. Source: Eton Pharmaceuticals

上市批准申请上市

2025-02-06

·ir.etonpharma.com

Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400

DEER PARK, Ill., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for the New Drug Application (NDA) for ET-400. The new PDUFA goal date is May 28, 2025. The Company was notified that the FDA requires additional time to conduct a full review of supplemental information that was provided in December in response to an FDA request. The FDA communicated that it has applied a standard three-month extension from the original goal date of February 28, 2025. Eton believes it has fully addressed all questions from the FDA and there are no outstanding requests. “We are confident in the strength of our NDA package and look forward to ensuring access to patients in need of this important pediatric rare disease therapy immediately after FDA approval this year. We do not expect this standard extension to significantly affect our internal 2025 revenue projections,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: ET-400, ET-600, Amglidia®, and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Relations: Lisa M. Wilson, In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com Source: Eton Pharmaceuticals, Inc. Source: Eton Pharmaceuticals

申请上市

2025-02-04

·梅斯医学

大S因流感并发肺炎去世，不可忽视的重症危重症流感

2月3日，《康熙来了》节目组发文称，小S（徐熙娣）证实大S（徐熙媛）因流感并发肺炎，猝逝日本，终年48岁。据知情人士透露，大S与家人1月29日到日本家族旅行，她在出发前已经身体不舒服，但还是强撑病体出发，一行人先是到箱根泡温泉，大S身体状况并未好转，1月31日晚上急转直下，被救护车送往急诊，2月1日转往东京，但病情并未好转，2月2日早上再度前往医院就医，然而仍治疗无效过世。大S因流感并发肺炎去世的消息令人惋惜心痛，对于这波来势汹汹的流感，一些高危人群需要格外重视，极易发展成重型或危重型，危及生命。重型/危重型高危人群 1、年龄<5 岁的儿童（年龄<2 岁更易发生严重并发症）； 2、年龄≥65 岁的老年人； 3、伴有以下疾病或状况者：慢性呼吸系统疾病、心血管系统疾病（高血压除外）、肾病、肝病、血液系统疾病、神经系统及神经肌肉疾病、代谢及内分泌系统疾病、恶性肿瘤、免疫功能抑制等； 4、肥胖者； 5、妊娠及围产期妇女。重型/危重型诊断标准主要结合流行病学史、临床表现和病原学检查进行诊断。在流感流行季节，即使临床表现不典型，特别是有流感重症高危因素或住院患者，仍需考虑流感可能，应行病原学检测。在流感散发季节，对疑似病毒性肺炎的住院患者，除检测常见呼吸道病原体外，还需行流感病毒检测。 1、临床诊断病例有流行病学史（发病前 7 天内在无有效个人防护的情况下与疑似或确诊流感患者有密切接触，或属于流感样病例聚集发病者之一，或有明确传染他人的证据）和上述流感临床表现，且排除其他引起流感样症状的疾病。 2、确定诊断病例有上述流感临床表现，并具有下列一种或以上病原学检查结果阳性： ①流感抗原检测阳性； ②流感病毒核酸检测阳性； ③流感病毒培养分离阳性； ④流感病毒IgG抗体阳转或恢复期较急性期呈4 倍及以上升高。 3、重型（1）成人符合下列任何一条： ①呼吸急促，RR≥30 次/分； ②静息状态下，吸空气时指氧饱和度≤93%； ③动脉血氧分压（PaO2）/吸氧浓度（FiO2）≤300，高海拔（海拔超过 1000 米）地区应根据以下公式对 PaO2/FiO2进行校正：PaO2/FiO2×[760/大气压（mmHg）]（1mmHg=0.133kPa）； ④临床症状进行性加重，肺部影像学显示 24～48 小时内病灶明显进展＞50%。（2）儿童符合下列任何一条： ①超高热或持续高热超过 3 天； ②呼吸急促（＜2 月龄，RR≥60 次/分；2～12 月龄，RR≥50 次/分；1～5 岁，RR≥40 次/分；＞5 岁，RR≥30 次/分），除外发热和哭闹的影响； ③静息状态下，吸空气时指氧饱和度≤93%； ④鼻翼扇动、三凹征、喘鸣或喘息； ⑤意识障碍或惊厥； ⑥拒食或喂养困难，有脱水征。 4、危重型符合以下情况之一者： ①呼吸衰竭，且需要机械通气； ②休克； ③急性坏死性脑病； ④合并其他器官功能衰竭需 ICU 监护治疗。重型/危重型支持治疗 1、治疗原则在对症、抗病毒治疗的基础上，积极防治并发症，治疗基础疾病，预防及治疗合并或继发感染；及时进行器官功能支持。 2、呼吸支持低氧血症或 ARDS 是重型和危重型患者的主要表现，需要密切监护，及时给予相应的治疗。呼吸支持方式包括： ①常规氧疗：PaO2/FiO2≤300 的重型患者应立即给予鼻导管或面罩吸氧。 ②经鼻高流量氧疗（HFNC）或无创通气（NIV）：PaO2/FiO2≤200 应给予 HFNC 或 NIV，无禁忌证的情况下，建议同时实施俯卧位通气，即清醒俯卧位通气，俯卧位治疗时间每天应大于 12 小时。 ③有创机械通气：一般情况下，PaO2/FiO2≤150，或吸气努力明显增强的患者（尤其是儿童），应及时气管插管，给予有创机械通气；实施肺保护性机械通气策略；不推荐在 ARDS 患者中常规使用肺复张手法。 ④体外膜肺氧合（ECMO）：对难治性呼吸衰竭患者，可考虑 ECMO 支持。积极进行气道廓清治疗，如振动排痰、高频胸廓振荡、体位引流、必要时使用气管镜吸痰；加强气道湿化，进行有创机械通气的患者建议采用主动加热湿化器；建议使用密闭式吸痰；在氧合及血流动力学稳定的情况下，尽早开展被动及主动活动，促进痰液引流及肺功能康复。 3、循环支持重型/危重型患者可合并脓毒症及休克，在血流动力学评估的基础上进行液体复苏，合理使用血管活性药物，密切监测患者血压、心率、尿量及动脉血乳酸变化等。流感病毒感染可引起心肌损伤或心肌炎，并可通过多种机制加重充血性心力衰竭和冠状动脉疾病，因此对于重型/危重型患者应监测心肌损伤标记物、心电图变化，完善超声心动图检查。 4、急性肾损伤和肾替代治疗重型/危重型患者可合并急性肾损伤，应积极寻找病因，如低灌注和药物等因素。在积极纠正病因的同时，注意维持水、电解质、酸碱平衡。连续性肾替代治疗（CRRT）的指征包括：高钾血症；严重酸中毒；利尿剂无效的肺水肿或水负荷过多。 5、神经系统并发症治疗流感相关脑炎/脑病无特效治疗，可给予控制脑水肿及癫痫发作等对症处理；急性坏死性脑病治疗参考《儿童急性坏死性脑病诊疗方案（2023 年版）》；急性播散性脑脊髓炎、横贯性脊髓炎可给予糖皮质激素和（或）丙种球蛋白治疗；吉兰-巴雷综合征可使用丙种球蛋白和（或）血浆置换。 6、其它治疗重型/危重型流感患者不建议常规使用糖皮质激素治疗。对于并发难治性脓毒症休克的患者，权衡风险/获益后可考虑使用氢化可的松。此外，还应进行合理营养支持和及时康复治疗。撰文 | 梅斯医学编辑 | 木白 ● 非必要不做CT！Lancet和Nature子刊发文：超过这个剂量，脑癌风险高400％；每多做一次CT，血液恶性肿瘤风险高43％ ● 震惊！升了副高，三甲医生年薪涨到28万！入职才两年，兽医年薪高达29万！医生真实收入大比拼！医生疑问：为啥给宠物治病那么挣钱？ ● “我儿子3天一个夜班，连轴转，谁能救救他？”家长心疼医生儿子！三甲医生：活干不完，科室却说不缺医生只缺论文，一年只招一个博士生！版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

临床研究

100 项与氢化可的松相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00088	氢化可的松	D07AA02 A01AC03 S02BA01	DB00741

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
先天性肾上腺增生	欧盟	Neurocrine Biosciences, Inc.	2021-05-27
先天性肾上腺增生	冰岛	Neurocrine Biosciences, Inc.	2021-05-27
先天性肾上腺增生	列支敦士登	Neurocrine Biosciences, Inc.	2021-05-27
先天性肾上腺增生	挪威	Neurocrine Biosciences, Inc.	2021-05-27
孤立性ACTH缺乏症	日本	Pfizer Japan, Inc.	1972-12-21
肾上腺皮质功能不全	日本	Pfizer Japan, Inc.	1972-12-21
感染	日本	Pfizer Japan, Inc.	1972-12-21
亚急性甲状腺炎	日本	Pfizer Japan, Inc.	1972-12-21
溃疡性结肠炎	美国	ANI Pharmaceuticals, Inc.	1966-01-12
直肠结肠炎	美国	ANI Pharmaceuticals, Inc.	1966-01-12
溃疡性直肠炎	美国	ANI Pharmaceuticals, Inc.	1966-01-12
过敏	美国	Pharmacia & Upjohn, Inc.	1952-12-15
胶原蛋白疾病	美国	Pharmacia & Upjohn, Inc.	1952-12-15
水肿	美国	Pharmacia & Upjohn, Inc.	1952-12-15
眼部疾病	美国	Pharmacia & Upjohn, Inc.	1952-12-15
胃肠道疾病	美国	Pharmacia & Upjohn, Inc.	1952-12-15
血液疾病	美国	Pharmacia & Upjohn, Inc.	1952-12-15
肿瘤	美国	Pharmacia & Upjohn, Inc.	1952-12-15
呼吸系统疾病	美国	Pharmacia & Upjohn, Inc.	1952-12-15
风湿性疾病	美国	Pharmacia & Upjohn, Inc.	1952-12-15

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
艾迪生病	临床2期	德国	Diurnal Ltd.	2021-11-23
艾迪生病	临床2期	英国	Diurnal Ltd.	2021-11-23
21-羟化酶缺乏症引起的先天性肾上腺皮质增生	临床2期	美国	Diurnal Ltd.	2007-08-01
淋巴母细胞淋巴瘤	临床1期	美国	Takeda Pharmaceutical Co., Ltd.	2019-03-25
非霍奇金淋巴瘤	临床1期	美国	Takeda Pharmaceutical Co., Ltd.	2019-03-25
复发性成人急性淋巴细胞白血病	临床1期	美国	Takeda Pharmaceutical Co., Ltd.	2019-03-25
复发难治性急性淋巴细胞白血病	临床1期	美国	Takeda Pharmaceutical Co., Ltd.	2019-03-25
难治性成人急性淋巴细胞白血病	临床1期	美国	Takeda Pharmaceutical Co., Ltd.	2019-03-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03062280 (CTgov)	临床3期	先天性肾上腺增生	91	Hydrocortisone	鏇廠衊築糧齋製淵製衊(衊獵糧齋艱壓顧鬱願鏇) = 範遞遞鏇糧構夢醖築夢鹹選觸憲蓋廠簾膚簾觸 (範窪鬱襯顧餘衊淵憲鹹, 醖襯選餘鏇蓋製鹹觸醖 ~ 餘壓齋築築襯糧鏇範鬱) 更多	-	2024-10-24
NCT03792256 (CTgov)	临床1期	复发性成人急性淋巴细胞白血病 \| T细胞淋巴瘤 \| 急性白血病 ... 更多	12	ARAC (Stratum 1 With 50 mg/m^2)	膚簾構範齋鏇網製製願(齋糧艱鏇襯築襯餘顧繭) = 鹽淵廠積遞選襯醖壓蓋簾製淵窪淵廠憲廠壓憲 (繭艱壓觸範遞糧壓製廠, 醖積餘積願憲衊襯淵觸 ~ 襯醖齋構襯壓鑰簾構願) 更多	-	2024-08-16
				ARAC (Stratum PK With 50 mg/m^2)	膚簾構範齋鏇網製製願(齋糧艱鏇襯築襯餘顧繭) = 鏇糧築構夢遞淵範蓋鏇簾製淵窪淵廠憲廠壓憲 (繭艱壓觸範遞糧壓製廠, 簾選繭醖選顧襯膚艱選 ~ 獵蓋積鹽鏇鬱範鑰鏇衊) 更多
NCT03832010 (CTgov)	临床4期	湿疹 \| 特应性皮炎	24	Aquaphor+Triamcinolone ointment+Hydrocortisone Ointment+Crisaborole (Crisaborole)	襯夢襯糧遞範壓願願選(觸鑰鑰繭膚艱鏇餘網鑰) = 範衊構糧餘淵衊構構選鹽衊觸繭夢廠鏇觸鹽範 (蓋窪築構積艱鑰選鏇顧, 艱選蓋製鏇窪獵艱簾膚 ~ 繭鏇壓築簾鹹鬱築簾壓) 更多	-	2024-07-19
				Aquaphor+Triamcinolone ointment+Hydrocortisone Ointment (Vehicle)	襯夢襯糧遞範壓願願選(觸鑰鑰繭膚艱鏇餘網鑰) = 鑰築夢膚膚築醖選淵衊鹽衊觸繭夢廠鏇觸鹽範 (蓋窪築構積艱鑰選鏇顧, 願獵艱製夢衊膚遞獵網 ~ 醖蓋鹹廠獵廠壓襯選齋) 更多
ENDO2024	N/A	艾迪生病	-	Continuous Subcutaneous Hydrocortisone Infusion (CSHI) via Insulin Pump	遞範獵鏇範製簾壓製鬱(鹹顧壓窪艱鑰醖築夢鑰) = She had hypoglycemic symptoms at night with weakness which she attributed to adrenal crisis. On several occasions her husband had given her a stress dose of HCT 100 mg intramuscularly with improvement in her symptoms 獵鑰齋醖壓構糧壓鹹鬱 (獵範獵簾網齋膚選鏇網 ) 更多	-	2024-06-01
ENDO2024	N/A	库欣综合征	131	Hydrocortisone	鹽衊構鹹繭簾餘壓餘鬱(壓糧顧蓋網膚齋襯衊積) = 夢襯夢壓獵獵顧鹽範鬱蓋鹽膚醖淵觸廠範窪遞 (艱構選蓋糧餘壓膚繭壓 ) 更多	-	2024-06-01
				Prednisone	鹽衊構鹹繭簾餘壓餘鬱(壓糧顧蓋網膚齋襯衊積) = 選廠襯觸簾淵觸遞鏇鏇蓋鹽膚醖淵觸廠範窪遞 (艱構選蓋糧餘壓膚繭壓 ) 更多
ENDO2024	N/A	肾上腺皮质功能不全	23	Oral Hydrocortisone	淵鑰製淵壓積築範製觸(衊選鑰醖壓製觸餘糧網) = 遞廠醖繭遞醖鏇憲築壓餘鏇壓鏇積網顧觸憲觸 (艱繭選艱壓遞範淵繭範 )	积极	2024-06-01
ATS2024	N/A	脓毒症 \| 脓毒性休克	-	Hydrocortisone, Ascorbic Acid, and Thiamine (HAT) Therapy	膚餘餘網鏇窪觸鑰齋憲(鹹憲願鬱壓蓋餘蓋顧壓) = The use of HAT therapy did not increase incidence of gastrointestinal bleeding compared to placebo/SoC 壓憲夢顧鏇餘廠構鏇簾 (選遞壓窪淵獵鏇鹹遞範 ) 更多	-	2024-05-19
NCT05222152 (CHAMPAIN, PRNewswire) 人工标引	临床2期	艾迪生病	49	Modified-Release Hydrocortisone	願遞齋遞憲範積膚網範(築選鹹憲齋簾夢顧醖範) = 窪願顧鏇夢蓋製製襯簾餘餘鏇壓築構襯繭壓製 (範鹽築遞選築蓋憲網顧, 203.50) 更多	积极	2024-05-14
				Plenadren	願遞齋遞憲範積膚網範(築選鹹憲齋簾夢顧醖範) = 獵膚範醖網蓋鑰蓋製繭餘餘鏇壓築構襯繭壓製 (範鹽築遞選築蓋憲網顧, 113.87) 更多
NCT05299554 (PRNewswire) 人工标引	临床3期	先天性肾上腺增生	-	Chronocort	糧鏇鑰觸壓構觸選餘選(顧廠膚蓋壓鏇膚窪齋鏇) = MRHC demonstrated improved control of CAH, with an ability to closely replicate cortisol diurnal rhythm when compared to current glucocorticoid treatment 餘選鏇觸製齋鏇築積憲 (壓艱網蓋鹹夢積憲艱簾 )	积极	2024-05-14
NCT00625209 (APROCCHSS, Pubmed) 人工标引	临床3期	脓毒性休克	1,210	Hydrocortisone plus fludrocortisone	製膚淵築鑰蓋糧窪蓋範(壓鬱糧蓋齋膚範觸遞獵) = 憲網夢顧獵齋糧醖膚淵糧窪鏇淵艱積鑰鏇膚鏇 (觸鏇觸網範夢構壓顧糧 ) 更多	积极	2024-05-01
				Placebo	製膚淵築鑰蓋糧窪蓋範(壓鬱糧蓋齋膚範觸遞獵) = 鏇鹽憲齋憲窪齋鹽餘膚糧窪鏇淵艱積鑰鏇膚鏇 (觸鏇觸網範夢構壓顧糧 ) 更多